42
DAFTAR PUSTAKA
1. Ni Han, Soew HHK, Htet A. Determinants of Abnormal Liver Function
Tests in Diabetes Patients in Myanmar. International Journal of Diabetes
Research 2012, 1(3): 36-41 DOI: 10.5923/j.diabetes.20120103.02
2. Perkumpulan Endokrinologi Indonesia. Konsensus Pengendalian dan
Pencegahan Diabetes Melitus tipe2 di Indonesia, PB. PERKENI.
Jakarta. 2011
3. Idris AS, Mekky KFH, Abdalla BEE, et all. Liver Function Test in Type 2
Sudanese Diabetic Patients. International Journal of Nutrition and
MetabolismVol 3(2). P:17-21. Febuari 2011.
4. Jayarama N, Sudha R. A Study of Non-Alcoholic Fatty Liver Disease
(Nafld) in Type 2 Diabetes Mellitus in a Tertiary Care Centre, Southern
India. Journal of Clinical and Diagnostic Research. 2012 April, Vol-6(2):
243-245
5. Tolman KG, Fonseca V, Dalpiaz V, et all. Spectrum of Liver Disease in
Type 2 Diabetes and Management of Patients With Diabetes and Liver
Disease. 2007 by the American Diabetes Association
6. Harris EH. Elevated Liver Function Tests in Type 2 Diabetes. CLINICAL
DIABETES • Volume 23, Number 3, 2005
7. Levinthal GN, Tavill AS. Liver Disease and Diabetes Mellitus.
CLINICAL DIABETES VOL. 17 NO. 2 1999
8. Perry IJ,Wannamethee SG, Shaper AG: Prospective study of serum
gamma –glutamyltransferase and risk of NIDDM. Diabetes Care 21:732–
737, 1998
9. Suyono S. Diabetes melitus di Indonesia. Dalam: Sudoyo AW, Setiyohadi
B, Alwi I, Simadibrata M, Setiati S, editor. Buku ajar ilmu penyakit dalam.
Edisi ke-5. Jakarta Pusat (JKT): Interna Publishing; 2009. Hal. 1873-9.
10.Khardori R. Type 2 diabetes mellitus. Medscape. 2013.
11.Powers AC. Diabetes mellitus. Dalam : Kasper DL, Fauci AS, Longo DL,
Braunwald E, Hauser SL, Jameson JL, editor. Harrison’s principles of
internal medicine. 16th ed. New York (USA): McGraw Hill Medical
Publishing Division; 2005. P. 2152-80.
43
12.American Diabetic Association. Standards of medical care in
diabetes-2012. Diabetes Care. Vol. 12, Supplement 1. diabetes-2012. DOI:
10.2337/dc12-s011
13.Lewis GF, Carpentier A, Khosrow A, Giacca A: Disordered fat storage
and mobilization in the pathogenesis of insulin resistance and type 2
diabetes. Endocr Rev 23:201–229, 2002.
14.Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS,
Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed
insulin resistance and sensitivity in livers of lipodystrophic and ab/ab
mice. Mol Cell 6:77–86, 2000.
15.Neuschwander-Tetri BA, Caldwell S: Nonalcoholic steatohepatitis:
summary of AASLD single topic conference. Hepatology 37:1202–1219,
2003.
16.Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor
necrosis factor promoter polymorphism with susceptibility to alcoholic
steatohepatitis. Hepatology 26:143–146, 1997
17.O’Brien RM, Granner DK: Regulation of gene expression by insulin.
Biochem J. 278:609–619, 1991
18.Wannamethee G, Ebrahim S, Shaper AG: Gamma-glutamyltransferase:
determinants and associations with mortality from ischaemic heart disease
and all causes. Am J Epidemio. 42:699–708, 1995.
19.Ohlson LO, Larsson B, Bjorntorp P, Erksson, H, Svardsudd K,Welin L,
Tibblin G,Wilhelmsen L: Risk factors for type 2 diabetes mellitus: thirteen
and one-half years of follow-up of the participants in a study of Swedish
men born in 1913.Diabetologia 31:798–305, 1988
20.Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C,
Tataranni PA: High alanine aminotransferases is associated with decreased
hepatic insulin sensitivity and predicts the development of type 2 diabetes.
Diabetes. 51:1889–1895, 2002
21.Salmela PI, Sotaniemi EA, Niemi M, Maentausta O: Liver function tests in
diabetic patients. Diabetes Care 7:248–254, 1984.
44
22.Erbey JR, Silberman C, Lydick E: Prevalence of abnormal serum alanine
aminotransferase levels in obese patients and patients with type 2 diabetes.
Am J Med 109:588–590, 2000.
23.Alba LM, Lindor K: Review Article: Nonalcoholic fatty liver disease.
Aliment PharmacolTher 17:977–986, 2003
24.Daniel S, Ben-Menachem T, Vasudevan G, Ma D, Blumenkehl M:
Prospective evaluation of unexplained chronic liver transaminase
abnormalities in asymptomatic and symptomatic patients. Am J
Gastroenterol 94:3010–3014, 1999
25.Skelly MM, James PD, Ryder SD: Findings on liver biopsy to investigate
abnormal liver function tests in the absence of diagnostic serology. J
Hepatol 35:195–199, 2001.
26.Baig NA, Herrine SK, Rubin R: Liver disease and diabetes mellitus. Clin
Lab Med 21:193–207, 2001
27.Knobler H, Schihmanter R, Zifroni A, Finakel G, Schattner A: Increased
risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C
virus infection. Mayo Clin Proc 75:355–359, 2000
28.Simo R, Hernandez C, Genesca J, Jardi R, Mesa J: High prevalence of
hepatitis C virus infection in diabetic patients. Diabetes Care 19:998–
1000, 1996
29.Pincus MR et al. Evaluation of liver funciton. In: Henry Clinical Diagnosis
and Management by Laboratory Methods. Ed : Richard A. McPherson.
Edisi 22. Elsevier. 2011
30.Roche. Cobas 6000. In : Roche diagnostik.
31.Akbar DH, Kwatner AH. Non-Alcoholic Fatty Liver Disease in Saudi type
2 Diabetic Subjects Who Attended a Medical Outpatient clinic :
Prevalance and Genera Characteristic-Observations. Diabetes Care 2003.
Desember 2003
45
32.Vishaldeep et al. A Comparative Study of Alanin Aminotransferase and
Alkaline Phospatase in Type-2 Diabetic-Patients and
Non-Diabetics.NJIRM 2014; 5(5). Scopmed Journal.
33. Lee D.H, Ha M.H, Kim J.H et al, Gamma-glutamyltransferase and
diabetes a 4 year follow - up study. Diabetologia (2004)
46: 359-364.
34.Sugondo, S., 2006. Obesitas Dalam: Sudoyono, W.A., Setiyohadi, B.,
Alwi, I., Simadibrata, M., & Setiati, S. Buku Ajar Ilmu Penyakit Dalam.
Jilid III. Edisi 4. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit
Dalam FKUI, 1919 - 1925.
